PRNewsWire
10 Jun 2026, 01:06 UTC · 14w ago
Verdict
Headline leans bearish. We score IMMP −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's Phase III TACTI-004 trial for futility.
So whatThe failure of a Phase III trial for a primary drug candidate is a catastrophic event for a biotech company's valuation and pipeline viability.
More negative than 99% of claims this week
A securities fraud class action lawsuit has been filed alleging Immutep misled investors regarding the efficacy and viability of its drug candidate.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 91% of claims this week
Immutep's ADR price collapsed approximately 83%, falling from $2.76 to $0.48 following the futility announcement.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company faces a class action lawsuit following an 83% stock price drop after a phase III trial was discontinued for futility.
More negative than 87% of ticker scores this week
The company is the subject of a class action lawsuit filed by Robbins LLP.
More negative than 87% of ticker scores this week
The company is the subject of a class action lawsuit filed by Robbins LLP.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
50m ago
−10.9%
Price agrees with the score
$0.3286 vs $0.3689 close before publication (Jun 9) · not market-adjusted
IMMP chart →
